Brief: Tempest Reports Year End 2025 Financial Results And Provides Business Update
30/03/2026 15:07
March 30 (Reuters) - Tempest Therapeutics Inc TPST.O: TEMPEST REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE TEMPEST THERAPEUTICS INC - APPOINTS MATT ANGEL AS CEO AND PRESIDENT TEMPEST THERAPEUTICS INC - ANNOUNCES POSITIVE INTERIM DATA FROM REDEEM-1 PHASE 1/2A TRIAL OF TPST-2003 TEMPEST THERAPEUTICS INC - REPORTS NET LOSS OF $26.3 MILLION AND NET LOSS PER SHARE OF $6.33 FOR 2025 Source text: ID:nGNX54qKQ6 Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T